Introduction
============

Photodynamic therapy (PDT) with verteporfin significantly reduces visual acuity (VA) loss in cases with subfoveal choroidal neovascularization (CNV) secondary to exudative age related macular degeneration (AMD) ([@b1-co-2-71]; [@b6-co-2-71]), as well as the patient's perception of scotoma ([@b32-co-2-71]). However, several sessions are frequently needed to achieve complete closure of the lesions (3.4 during the first year, 2.2 during the second year and 1.3 during the third year) as was demonstrated by the results of randomized clinical trials ([@b1-co-2-71]; [@b6-co-2-71]; [@b5-co-2-71]) and the final VA outcome is usually considered not good enough by the patient and the ophthalmologist.

It has been reported that CNV permeabilization and growth associated with exudative AMD make it necessary to perform repeated PDT sessions, reducing its cost-effectiveness ([@b33-co-2-71]; [@b19-co-2-71]; [@b7-co-2-71]). Repeated PDT sessions may cause retinal damage and result in progressive thinning of the neurosensory retina ([@b25-co-2-71]; [@b23-co-2-71]), as well as closure of normal choroidal vessels ([@b20-co-2-71]).

Combined therapies have been considered necessary to reduce the number of re-treatments and the progressive loss of VA. Intravitreal triamcinolone acetonide (TA) has been associated with PDT in order to join the short-term effect of PDT-induced CNV closure ([@b19-co-2-71]) and the antiangiogenic and anti-inflammatory effects of TA ([@b34-co-2-71]). Intravitreal injection of TA is cheap and relatively safe, and TA appears to have a long half-life in the vitreous cavity ([@b36-co-2-71]).

We have tried to determine the benefits of combining the short-term effect of PDT-induced CNV closure ([@b21-co-2-71]), with the antiangiogenic and anti-inflammatory effects of TA ([@b36-co-2-71]).

Material and methods
====================

We analyzed the results of combined PDT and high dose TA in 30 eyes from 30 patients with AMD-associated CNV at the Alicante Institute of Ophthalmology at 12 and 24 month follow-up. The study was performed in accordance to the ethical standards of the 1964 Declaration of Helsinki, and data gathering was performed after obtaining written informed consent and approval of the Ethics Committee.

Patients older than 50 years of age with AMD-associated subfoveal CNVs verified by fluorescein angiography (FA) were included. CNVs occupied more than 50% of total lesion area; greatest linear dimension of the lesion was less than 5400 μm and baseline intraocular pressure (IOP) was under 21 mmHg.

Three groups of patients were considered. Group 1 comprised 15 naïve patients; Group 2 comprised 15 patients who had previously received PDT and showed persistent leakage on FA. We also considered 15 patients with AMD-associated subfoveal CNV who had been treated at our clinic with standard PDT as a Control Group. The three groups were not significantly different for age, sex, best corrected visual acuity (BCVA), CNV size, and lesion type at baseline ([@b30-co-2-71]).

Conventional PDT as previously described ([@b1-co-2-71]) was followed by an intravitreal injection of 19.4 ± 2.1 mg TA in 0.1 ml five days later. This concentration of TA was obtained by allowing the 40 mg/ml triamcinolone suspension to precipitate within the injecting syringe ([@b29-co-2-71];[@b30-co-2-71]; [@b31-co-2-71]).

CNV leakage or growth demonstrated by FA was treated by additional PDT sessions not sooner than three months later. New TA injections were performed combined with PDT at six months intervals, when necessary.

Main outcome variables were BCVA at baseline and at month 12 and 24 (LogMAR), changes in visual acuity (Snellen lines), number of PDT sessions per patient, and appearance of adverse events.

Results
=======

Demographics have been previously described ([@b30-co-2-71]; [@b31-co-2-71]). Three patients in Group 2 had been treated by PDT once; six patients twice; four patients three times; one patient four times; and one patient six times ([@b30-co-2-71]; [@b31-co-2-71]).

One patient (case 14) was excluded from Group 1 at month 3 due to migration of triamcinolone into the anterior chamber. One patient (case 2) in Group 2 lived far from the medical center and refused to return for follow-up visits.

Differences between baseline and 12 month BCVA for Groups 1 and 2 were not statistically significant (p = 0.49 and p = 0.10 respectively, Student t test for paired data). BCVA in the Control Group at month 12 was significantly worse than in Groups 1 and 2 (p = 0.004, ANOVA). The changes in BCVA during the second year compared with baseline were not statistically significant for Groups 1 and 2 (p = 0.94 and p = 0.34 respectively, Student t test for paired data). BCVA in the Control Group was significantly worse (p = 0.04, Student t test for paired data).

The presence of fluorescein leakage and the need for PDT are shown in [Table 1](#t1-co-2-71){ref-type="table"}. The difference in the number of PDT sessions needed to stop FA leakage was statistically significant at months 3, 6, 9, and 12 for Groups 1 and 2 compared to the historical Control Group. The average number of PDT sessions for the two-year period was 3.9 for the Control Group, 1.9 for Group 1 and 1.2 for Group 2. The average number of intravitreal TA injections was 1.5 in Group 1 and 1.2 in Group 2. A second injection was needed in nine eyes during the 2 year follow-up.

Fifteen (54%) of 28 eyes from Groups 1 and 2 had high IOP needing medical therapy during the first year. There were no cases of increased IOP in the Control Group. No new cases of IOP elevation appeared during the second year. Two eyes with high IOP needed a second intravitreal TA injection at month 15, which did not affect IOP.

IOP rose in five cases one month after the injection, in four cases at month 3, in four cases at month 6, in one case at month 7, and in one case at month 9. One single topical drug controlled IOP in seven cases; two drugs were needed in seven cases, and one case underwent 180° diode laser cycloablation. The number of patients needing therapy to control IOP decreased progressively, and by the end of the second year only 6 of 26 eyes (23%) still needed topical treatment to control IOP: two patients with two drugs, and four patients with one drug. Systemic drugs were not needed to control IOP.

Crystalline lens opacification (defined by a 2-level increase in lens opacity according to The Lens Opacities Classification System III ([@b9-co-2-71]) appeared in 12 eyes (55%) from 22 phakic eyes in groups 1 and 2 completing 24 month follow-up and in none of the eyes from the historical control group. Cataract surgery was performed without complications in these cases.

Floaters were described by patients in the first few days after the injection and disappeared later in all cases. One case in Group 2 (case 13) suffered a central retinal vein occlusion at month 12. TA migrated into the anterior chamber in one case the day after the injection ([@b28-co-2-71]). There were no cases of endophthalmitis.

Discussion
==========

PDT is known to increase local production of vascular endothelial growth factor (VEGF), what might be linked with frequent recurrences ([@b38-co-2-71]). Patients treated by PDT alone have been reported to need repeated PDT sessions in 90.8% of the cases at month-3 and slightly less at month-6, with an average 3.3 sessions in the first year of therapy, and an average loss of 2.2 lines at month 12 ([@b1-co-2-71]).

The development of new anti-VEGF drugs ([@b13-co-2-71]; [@b4-co-2-71]) and the knowledge on the inhibitory role of steroids in the production of VEGF offer new approaches to the treatment of CNV.

The association of PDT and intravitreal TA to treat subfoveal CNV secondary to AMD has been reported by several groups ([@b15-co-2-71]; [@b34-co-2-71]; [@b3-co-2-71]; [@b30-co-2-71]).

A number of non-randomized studies have shown that the frequency of PDT sessions is reduced with combined therapy. Combined PDT-TA (4 mg) results in a better outcome than PDT alone, with reduction of the number of PDT sessions to 1.24 over the first year and improved VA outcome by 2.5 lines after 12 months follow-up ([@b8-co-2-71]). The need to retreat was reduced to 3 of 14 eyes, with a favorable visual outcome in most of the treated patients ([@b22-co-2-71]). Spaide reported that the association of PDT and 4 mg intravitreal TA significantly improved average visual acuity by 2.5 lines at 12-month follow-up. The rate of re-treatment was 1.24 for naïve eyes and 1.2 for eyes previously treated by PDT alone over the first year ([@b34-co-2-71]; [@b35-co-2-71]). Rechtman has reported 21% of eyes needing PDT re-treatment after combined therapy with PDT and 4 mg TA, with a favorable visual outcome after six to twelve months follow-up ([@b24-co-2-71]).

Our results with 19.4 ± 2.1 mg/0.1 ml TA agree with others injecting higher doses (25 mg/0.1 ml TA) ([@b2-co-2-71]; [@b3-co-2-71]; [@b22-co-2-71]; [@b29-co-2-71]; [@b30-co-2-71]). Augustin and Schmidt-Erfurth treated 184 eyes with AMD secondary to CNV by PDT and 25 mg intravitreal TA 16 hours later, and followed them for more than 6 months ([@b3-co-2-71]). VA improvement averaged 1.22 Snellen lines after an average 1.21 sessions of PDT. The response to the combined therapy was good and did not depend on the lesion composition or size. The same authors have reported the outcome of pure occult lesions in 41 eyes with the same combined therapy ([@b2-co-2-71]). VA improved in average from 20/133 at baseline to 20/81 at two years after an average 1.8 PDT sessions. Nicolo et al reported 11 eyes from 10 patients with occult CNV treated by 25 mg intravitreal TA followed by PDT one month later. VA improved from an average 20/160 to 20/80 at one year ([@b22-co-2-71]).

Theoretical risks of intravitreal TA injections include endophthalmitis, high IOP, cataract progression, retinal tear, retinal detachment and floaters. A prolongation of choroidal hypofluorescence following PDT and intravitreal TA has been reported recently ([@b18-co-2-71]). The frequency of complications associated with the use of high TA dose does not seem to be higher in the series reported ([@b2-co-2-71]; [@b3-co-2-71]; [@b22-co-2-71]; [@b29-co-2-71]; [@b30-co-2-71]).

Spaide et al ([@b34-co-2-71]; [@b35-co-2-71]) and Rechtman et al ([@b24-co-2-71]) have reported increased IOP in 29%--38% of eyes after 4 mg TA. Augustin and Schmidt-Erfurth have reported high IOP (\>25 mmHg) in 22 to 25% of eyes after 25 mg TA in two different clinical series ([@b2-co-2-71]; [@b3-co-2-71]).

Cataract progression has already been described by several authors. [@b12-co-2-71] reported cataract surgery in 24% of eyes 25 months after 4 mg TA injection. Augustin and Schmidt-Erfurth described cataract surgery in 49% and 42% of eyes treated by high dose intravitreal TA injection, respectively ([@b2-co-2-71]; [@b3-co-2-71]).

No association between increased IOP and lens opacification was noticed in our series during the second year, though it has been described previously ([@b12-co-2-71]).

We have encountered no cases of endophthalmitis, retinal tear or retinal detachment as previously reported ([@b34-co-2-71]; [@b35-co-2-71]; [@b2-co-2-71]; [@b3-co-2-71]; [@b22-co-2-71]). However, these series are small, and the power to detect these potentially severe complications is low.

The interval between PDT and TA injection is under discussion. We performed TA injection after PDT in order to avoid opacification of the vitreous body by TA which might block laser irradiation, and the inhibition of free-radical formation ([@b11-co-2-71]) interfering with the mechanism of action of PDT ([@b39-co-2-71]). The five day interval between PDT and intravitreal TA was chosen in order to avoid the photosensitizing effect of verteporfin in the event that any problem such as retinal detachment or endophthalmitis might appear after the injection, and before reperfusion or new vessel growth might take place.

The advantages of combining high dose intravitreal TA to PDT are a substantial reduction in the number of PDT sessions and of intravitreal injections.

Increased IOP and cataracts are side effects to be considered. The advantage of using high doses of intravitreal TA is to achieve a longer permanence of the drug in the vitreous cavity instead of 3 months achieved with 4 mg intravitreal TA, reducing the need to repeat the injection ([@b36-co-2-71]). However we may also expect a longer duration of the side effects, especially of increased IOP. According to our results we can not conclude that high dose (20 mg) intravitreal TA is better than low dose (4 mg).

The good VA results achieved by antiangiogenic drugs and the low rate of adverse events have reduced the indications of PDT associated to intravitreous TA ([@b26-co-2-71]). However, the use of intravitreous antiangiogenic drugs is limited by the need of repeated intraocular injections and the inherent risks of endophthalmitis associated with this procedure, since antiangiogenic drugs do not permanently close CNV, and it is not known how early exudation may reappear after cessation of treatment.

The association of antiangiogenic drugs to PDT might be a solution to this problem. The combined treatment PDT and ranibizumab seems to be more effective than PDT alone ([@b14-co-2-71]) and does not seem to increase adverse events compared with PDT alone in normal monkey eyes ([@b17-co-2-71]). The association of PDT with intravitreal ranibizumab has been reported in the FOCUS and the PROTECT clinical trials ([@b27-co-2-71]). The preliminary results of these trials suggest that even though this association is safe and may reduce the number on ranibizumab injections required to achieve the inactivation of CNV, it may also reduce the benefits of ranibizumab. A retrospective study on 24 eyes treated by PDT and intra-vitreous bevacizumab demonstrated 2.04 Snellen lines mean improvement in VA ([@b10-co-2-71]). Fifteen eyes (63%) required only a single combined treatment for CNV resolution and the combined therapy was followed by no complications, including endophthalmitis, uveitis, and ocular hypertension. The association of PDT and intravitreal bevacizumab may also be useful in treating neovascular AMD by reducing retreatment rates and improving visual acuity. However, CNV is influenced by several mediators, many of them inflammatory, and not only by VEGF ([@b16-co-2-71]; [@b37-co-2-71]). Intravitreous TA may help blocking these inflammatory factors with a long standing effect due to its depot effect. We consider that TA associated with anti VEGF drugs and PDT may still have a role in the treatment of CNV secondary to AMD.

###### 

Number of PDT sessions performed

  Month   Control group   Group 1      Group 2      Statistical significance[a](#tfn1-co-2-71){ref-type="table-fn"}
  ------- --------------- ------------ ------------ -----------------------------------------------------------------
  3       14/15 (93%)     5/14 (36%)   1/15 (7%)    p \< 0.000
  6       10/15 (67%)     3/14 (21%)   2/15 (13%)   p = 0.004
  9       7/15 (47%)      1/14 (7%)    0/14 (0%)    p = 0.032
  12      5/15 (33%)      0/14 (0%)    0/14 (0%)    p = 0.005
  15      2/14 (14%)      2/14 (14%)   0/14 (0%)    NS
  18      2/14 (14%)      1/14 (7%)    0/14 (0%)    NS
  21      0/13 (0%)       0/13 (0%)    0/13 (0%)    NS
  24      0/13 (0%)       0/13 (0%)    0/13 (0%)    NS

Chi square test.

**Abbreviation:** NS, not statistically significant.
